218 related articles for article (PubMed ID: 30314457)
1. The efficacy and safety of anti-interleukin-6 receptor monoclonal blockade in a renal transplant patient with Castleman disease: early post-transplant outcome.
Matsunami M; Ubara Y; Sumida K; Oshima Y; Oguro M; Kinoshita K; Tanaka K; Nakamura Y; Kinowaki K; Ohashi K; Fujii T; Igawa T; Sato Y; Ishii Y
BMC Nephrol; 2018 Oct; 19(1):263. PubMed ID: 30314457
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Tocilizumab (Anti-Interleukin-6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-Sensitized Renal Allograft Recipients.
Choi J; Aubert O; Vo A; Loupy A; Haas M; Puliyanda D; Kim I; Louie S; Kang A; Peng A; Kahwaji J; Reinsmoen N; Toyoda M; Jordan SC
Am J Transplant; 2017 Sep; 17(9):2381-2389. PubMed ID: 28199785
[TBL] [Abstract][Full Text] [Related]
3. Short-term efficacy of the IL6 receptor antibody tocilizumab in patients with HIV-associated multicentric Castleman disease: report of two cases.
Nagao A; Nakazawa S; Hanabusa H
J Hematol Oncol; 2014 Jan; 7():10. PubMed ID: 24438824
[TBL] [Abstract][Full Text] [Related]
4. Impact of Tocilizumab (Anti-IL-6R) Treatment on Immunoglobulins and Anti-HLA Antibodies in Kidney Transplant Patients With Chronic Antibody-mediated Rejection.
Shin BH; Everly MJ; Zhang H; Choi J; Vo A; Zhang X; Huang E; Jordan SC; Toyoda M
Transplantation; 2020 Apr; 104(4):856-863. PubMed ID: 31385933
[TBL] [Abstract][Full Text] [Related]
5. Lung transplantation for idiopathic multicentric Castleman disease: potential efficacy and tolerability of a humanized anti-interleukin-6 receptor monoclonal antibody.
Tomioka Y; Otani S; Tanaka S; Shien K; Suzawa K; Miyoshi K; Yamamoto H; Okazaki M; Sugimoto S; Yamane M; Toyooka S
Surg Case Rep; 2021 Sep; 7(1):209. PubMed ID: 34533616
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment of a mesangial proliferative glomerulonephritis with interstitial nephritis associated with Castleman's disease by an anti-interleukin-6 receptor antibody (tocilizumab).
Otani N; Morishita Y; Oh I; Saito O; Takemoto F; Muto S; Kusano E
Intern Med; 2012; 51(11):1375-8. PubMed ID: 22687845
[TBL] [Abstract][Full Text] [Related]
7. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation.
Vincenti F; Ramos E; Brattstrom C; Cho S; Ekberg H; Grinyo J; Johnson R; Kuypers D; Stuart F; Khanna A; Navarro M; Nashan B
Transplantation; 2001 May; 71(9):1282-7. PubMed ID: 11397963
[TBL] [Abstract][Full Text] [Related]
8. Tocilizumab histologically improved AA renal amyloidosis in a patient with multicentric Castleman disease: A case report
.
Yamada Y; Ueno T; Irifuku T; Nakashima A; Doi S; Ichinohe T; Masaki T
Clin Nephrol; 2018 Sep; 90(3):232-236. PubMed ID: 29701172
[TBL] [Abstract][Full Text] [Related]
9. Maintenance immunosuppression with intermittent intravenous IL-2 receptor antibody therapy in renal transplant recipients.
Gabardi S; Catella J; Martin ST; Perrone R; Chandraker A; Magee CC; McDevitt-Potter LM
Ann Pharmacother; 2011 Sep; 45(9):e48. PubMed ID: 21811001
[TBL] [Abstract][Full Text] [Related]
10. A Phase I/II Trial of the Interleukin-6 Receptor-Specific Humanized Monoclonal (Tocilizumab) + Intravenous Immunoglobulin in Difficult to Desensitize Patients.
Vo AA; Choi J; Kim I; Louie S; Cisneros K; Kahwaji J; Toyoda M; Ge S; Haas M; Puliyanda D; Reinsmoen N; Peng A; Villicana R; Jordan SC
Transplantation; 2015 Nov; 99(11):2356-63. PubMed ID: 26018350
[TBL] [Abstract][Full Text] [Related]
11. Sustained remission of multicentric Castleman disease in children treated with tocilizumab, an anti-interleukin-6 receptor antibody.
Galeotti C; Boucheron A; Guillaume S; Koné-Paut I
Mol Cancer Ther; 2012 Aug; 11(8):1623-6. PubMed ID: 22638145
[TBL] [Abstract][Full Text] [Related]
12. Induction Therapies in Live Donor Kidney Transplantation on Tacrolimus and Mycophenolate With or Without Steroid Maintenance.
Tanriover B; Zhang S; MacConmara M; Gao A; Sandikci B; Ayvaci MU; Mete M; Tsapepas D; Rajora N; Mohan P; Lakhia R; Lu CY; Vazquez M
Clin J Am Soc Nephrol; 2015 Jun; 10(6):1041-9. PubMed ID: 25979971
[TBL] [Abstract][Full Text] [Related]
13. Rescue therapy with tacrolimus and mycophenolate mofetil does not prevent deterioration of graft function in C4d-positive chronic allograft nephropathy.
Schwarz C; Regele H; Huttary N; Wahrmann M; Exner M; Nagy-Bojarsky K; Kletzmayr J; Hörl WH; Böhmig GA
Wien Klin Wochenschr; 2006 Jul; 118(13-14):397-404. PubMed ID: 16865644
[TBL] [Abstract][Full Text] [Related]
14. Kidney transplantation for end-stage renal failure in liver transplant recipients with hepatitis C viral infection.
Molmenti EP; Jain AB; Shapiro R; Scantlebury V; Lee R; Totsuka E; Flohr J; Rakela J; Fung JJ
Transplantation; 2001 Jan; 71(2):267-71. PubMed ID: 11213072
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment with tocilizumab for refractory anemia and slowly progressive renal glomerulosclerosis in multicentric Castleman disease: A case report.
Sugawara E; Sato T; Amasaki Y; Katsumata K
Medicine (Baltimore); 2022 Feb; 101(8):e28941. PubMed ID: 35212301
[TBL] [Abstract][Full Text] [Related]
16. Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status.
Swiatecka-Urban A
Paediatr Drugs; 2003; 5(10):699-716. PubMed ID: 14510627
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
[TBL] [Abstract][Full Text] [Related]
18. Prevention of early acute rejection with daclizumab and triple immunosuppression in cadaveric renal allograft recipients.
Kandus A; Grego K; Bren AF
Ther Apher Dial; 2005 Jun; 9(3):262-4. PubMed ID: 15967003
[TBL] [Abstract][Full Text] [Related]
19. Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation.
Clark G; Walsh G; Deshpande P; Koffman G
Nephrol Dial Transplant; 2002 Jul; 17(7):1304-9. PubMed ID: 12105256
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Eculizumab Therapy for Atypical Hemolytic Uremic Syndrome Recurrence and Antibody-Mediated Rejection Progress After Renal Transplantation With Preformed Donor-Specific Antibodies: Case Report.
Yamamoto T; Watarai Y; Futamura K; Okada M; Tsujita M; Hiramitsu T; Goto N; Narumi S; Takeda A; Kobayashi T
Transplant Proc; 2017; 49(1):159-162. PubMed ID: 28104125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
